Navigation Links
InterMune to Release Third Quarter Financial Results on November 3
Date:10/27/2011

BRISBANE, Calif., Oct. 27, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter 2011 financial results at the close of the U.S. markets on Thursday, November 3, 2011.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 22885421.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 22885421.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biom
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
2. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
3. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
4. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune Reports Third Quarter 2010 Financial Results
7. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
8. InterMune to Release Second Quarter Financial Results on July 27
9. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
10. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
11. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... BOCA RATON, Fla. , Nov. 25, 2014 ... has entered into a multi-product ANDA agreement with ... Maryland ) under which Breckenridge and Pii ...  Under the terms of the agreement, Pii will ... will market and distribute the products under its ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... 1 Older adults who exercise regularly show increased cerebral blood flow ... to findings presented today at the annual meeting of the Radiological Society ... The study, conducted at the University of North Carolina ( ... of older adults who exercise to brain scans of those who do ...
... New study finds the majority of acute lymphoblastic leukemia relapse ... of diagnosis , , MEMPHIS, ... Hospital have identified distinctive genetic changes in the cancer cells ... The finding offers a pathway to designing treatments for ALL ...
Cached Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3
(Date:11/27/2014)... Luciana Lagana and her husband ... Omadox, a feature film that received 9 awards at the ... ensemble cast. It is also an official selection of the ... a successful cinematic career for James Noel, a young filmmaker ... enjoy experimental mystery, filmed in glorious black and white, watching ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... By Dennis Thompson ... -- An experimental Ebola vaccine appears to be safe and ... the deadly virus, according to early clinical trial results reported ... of the phase I clinical trial for the vaccine paves ... nations of Liberia and Sierra Leone as early as January, ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Sciences Corporation announced,today a new initiative that ... instruments used in medical practice and healthcare,2.0 ... draws upon the,cognitive and anthropologic sciences, is ... human intelligence,s reliance on,narrative for richly conveying ...
... Build Healthy Communities, VICTORVILLE, Calif., April 16 ... Victorville Earth Day Eco Tote giveaway.,On Tuesday, April ... will be handing out recyclable Eco Totes to ... Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical Group ...
... have discovered sleep patterns in a type of anesthesia ... snooze. , The anesthetic used in the study, known ... tool to more thoroughly investigate ways of treating sleep ... one of the studys co-authors and an associate professor ...
... AFL ) announced today that it will ... on April 23, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO ... release, Aflac Incorporated will,webcast a conference call scheduled ... the teleconference, Aflac Incorporated Chairman and CEO Dan ...
... middle could be making us hungrier, so we eat more, ... Dr. Yaiping Yang and his colleagues at the Lawson Health ... abdominal fat tissue can reproduce a hormone that stimulates fat ... in the way we think about and treat abdominal obesity. ...
... Management Program improves patient care while ... saving ... of its inaugural Best Practices in Consumer Empowerment and,Protection Awards ... NeuroScience, Inc. and Eli Lilly,and Company as Silver Award winners ...
Cached Medicine News:Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 2Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 3Health News:Aflac Incorporated To Release First Quarter Results on April 23, 2008 2Health News:Your belly fat could be making you hungrier 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4